The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
about
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseasePharmacologic therapy for inflammatory bowel disease refractory to steroidsTherapeutic drug monitoring in inflammatory bowel diseaseVagus nerve stimulation: from epilepsy to the cholinergic anti-inflammatory pathwayWithdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel diseaseReview article: the role of anti-TNF in the management of ulcerative colitis -- past, present and futureOptimising monitoring in the management of Crohn's disease: a physician's perspectiveEfficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled TrialsNext-Generation Therapeutics for IBDBiologics in oral medicine: oral Crohn's disease and orofacial granulomatosisAltered colonic mucosal Polyunsaturated Fatty Acid (PUFA) derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiologyConcomitant herpes simplex virus colitis and hepatitis in a man with ulcerative colitis: Case report and review of the literature.Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.Herpes simplex virus encephalitis during treatment with etanercept.Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort.Biological treatment of Crohn's disease.Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement.Discontinuation of Scheduled Infliximab in Crohn's Patients With Clinical Remission: A Retrospective Single-Center Study.Combination therapy for inflammatory bowel diseaseInflammatory bowel disease: Efficient remission maintenance is crucial for cost containment.Inflammatory bowel diseases: Current problems and future tasks.Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy.Performance of the Montreal classification for inflammatory bowel diseasesCancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trialPediatric inflammatory bowel disease in Greece: 30-years experience of a single center.Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's diseaseOlder age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease.Infliximab to treat Crohn's disease: an update.Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's diseaseVariation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States.Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.What is the impact of age on adult patients with inflammatory bowel disease?Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways.Clinical predictors of thiopurine-related adverse events in Crohn's disease.A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel diseaseBiological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: a US Medicare cohort study.
P2860
Q26745721-64856035-81E8-4C19-8EA0-3CE4B3B7A0B3Q26796415-5AD042BA-4F27-493B-9270-FB959F46836BQ26852729-73BE98A1-A403-408F-9993-4A06E466B75FQ26858806-F9BE1293-7B39-47C7-930F-9339B01A7687Q26866281-ED0AB63B-045B-4586-8873-B49FDBED646EQ26992012-3E756FE0-C03A-498D-A42F-786401E031DCQ27007083-8AC3C21E-7F84-406E-8306-6B1AE266D0C7Q28070298-63600D40-FEF5-4A8E-B7B6-66DB57376029Q28082306-467B978F-F553-4735-8ADD-C65A4B418645Q28261955-5994019B-1E2E-4C07-A58D-9B8F0D1BEDC7Q28534532-2DAB985B-05E6-4B2C-998E-D70C563C7011Q30244327-8018A413-800A-4F0A-9C3E-EBA361288D3EQ30393052-C632FABB-3B45-450D-B228-95055ABCB08DQ30694936-36657457-0545-4181-A718-056E087770D1Q30844786-698C24F6-3D53-405D-8A4A-F0513946B7CDQ30902172-27F30DBA-7E65-45D8-B80C-C176C73A2409Q30991140-54628A46-9190-4597-895E-A1B74779AE1EQ33354991-BAD92F96-AA27-47C1-86F5-A56DED8D19A4Q33562796-DA80EA7C-BD71-4481-9635-24E9A18BECF7Q33625252-01B41D84-BD34-4469-BA0A-9AFA4BA99492Q33646452-B0F4939D-603D-4631-9BEC-C081C9933B34Q33646458-A0606B13-192B-4305-9AED-DA58A0CC6A00Q34047672-C9567165-B7EC-4AB3-904F-AB900878C869Q34267149-5F19D1F5-4BE7-47AC-BF66-4A71A9904408Q34303155-364CBAA3-0FD4-42B9-9E66-9C3125989915Q34467297-3B547D13-1DC6-4D5D-9867-47E3DE905469Q34520662-CCA1F217-8F4D-4D3D-9D4A-71E4D25BD041Q34767921-E95E81A2-28C8-4FD8-8739-9F69647CF467Q34907483-7C0BF05F-FD59-43CF-BA8C-F920395ECEDEQ35128238-9A0CA121-F2EA-4B8D-8D8A-702449C38889Q35134059-1B619889-A42A-4196-95A5-B466745B1CB4Q35304737-54DE2278-140E-4558-8DAB-0A4EEC4A1349Q35498214-ECD76CE9-7181-481A-B1A7-7AAAAFEB1BA0Q35634719-0C5A0B03-9513-4649-BEC7-7E6EE5848E4CQ35670680-69DF4636-360B-4D56-9D3C-7D856BE85147Q35714154-9363456F-148D-4E59-B923-5D5DBEE4CFF3Q35755435-A6CD3C7E-B3B9-4A73-A3A1-B253CD206D9BQ35819552-07F9C053-5DA6-4759-BECB-F208FA45A337Q35973766-92249A49-6DCA-47FD-B01D-6DBC28CD5BACQ36038958-0DCB389D-7782-47C1-A0CA-78EF6E532603
P2860
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The London Position Statement ...... , and how to predict response?
@ast
The London Position Statement ...... , and how to predict response?
@en
The London Position Statement ...... , and how to predict response?
@nl
type
label
The London Position Statement ...... , and how to predict response?
@ast
The London Position Statement ...... , and how to predict response?
@en
The London Position Statement ...... , and how to predict response?
@nl
prefLabel
The London Position Statement ...... , and how to predict response?
@ast
The London Position Statement ...... , and how to predict response?
@en
The London Position Statement ...... , and how to predict response?
@nl
P2093
P2860
P50
P356
P1476
The London Position Statement ...... , and how to predict response?
@en
P2093
Bret Lashner
Bruce Sands
Corey Siegel
Daan W Hommes
G Watermeyer
Geert R D'Haens
Hans Herfarth
M Watanabe
P2860
P304
199-212; quiz 213
P356
10.1038/AJG.2010.392
P407
P577
2010-11-02T00:00:00Z